 Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Incidence and risk factors of herpes zoster in patients with rheumatoid arthritis treated with upatinib

Ann Rheum Dis: Incidence and risk factors of herpes zoster in patients with rheumatoid arthritis treated with upatinib

 Last Update: 2021-10-19
 Source: Internet
 Author: User

Tags

1 3 diene

1 2 block

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Upatinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA)
.

JAK inhibitors are associated with an increased risk of herpes zoster (HZ) in RA patients

Rheumatoid arthritis

Recently, Annals of the Rheumatic Diseases, a top journal in the field of rheumatism, published a research article that aims to evaluate the incidence and risk factors of HZ in RA patients receiving UPA treatment from the UPA Phase III clinical trial project
.

In six randomized phase III trials (data cutoff date is June 30, 2020), researchers determined the HZ exposure adjustment rate/event rate of patients receiving UPA (monotherapy or combination therapy)
.

The incidence and event rate of HZ were also determined in patients receiving methotrexate (MTX) monotherapy or adalimumab (ADA) + MTX treatment

A total of 5306 patients were included in this analysis
.

The incidence of HZ in the MTX monotherapy group, ADA+MTX, 15mg UPA and 30mg UPA treatment groups was 0.

It can be seen that compared with ADA+MTX or MTX monotherapy , UPA has a higher incidence of HZ and event rate, and compared with a dose of 30mg and 15mg, the incidence of HZ and event rate is higher
.

Patients from Asia and a previous history of HZ may have an increased risk of HZ when receiving UPA treatment

Compared with ADA+MTX or MTX monotherapy, UPA has a higher incidence and event rate of HZ, and compared with a dose of 30mg and 15mg, the incidence of HZ and event rate is higher

Original source:

Kevin L Winthrop,et al.

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Melatonine 99

CAS No.: 73-31-4

pharmaceutical grade

$100/KG FOB

China Largest Manufacturer Supply High Purity ISOPRINOSINE CAS 36703-88-5

CAS No.: 36703-88-5

Pharmacy Grade

$3-3.5/KG FOB

API Rapamycin Powder 53123-88-9 99% Sirolimus powder

CAS No.: 53123-88-9

Pharmacy Grade

$2-2.5/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.